- Q1 2024 Cardiff Oncology Inc Earnings Call TranscriptMay 02, 2024$4.48 (+5.91%)Earnings
- Q4 2023 Cardiff Oncology Inc Earnings Call TranscriptFeb 29, 2024$1.77 (-3.02%)Earnings
- Q3 2023 Cardiff Oncology Inc Earnings Call TranscriptNov 02, 2023$1.14 (+8.57%)Earnings
- Cardiff Oncology Inc Clinical Update Call TranscriptSep 26, 2023
- Cardiff Oncology Inc Clinical and Corporate Update Call TranscriptAug 07, 2023
- Cardiff Oncology Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Cardiff Oncology Inc at Cowen Health Care Conference- GI/GU Oncology Panel TranscriptMar 07, 2023
- Cardiff Oncology Inc at JMP Securities Hematology Oncology Summit (Virtual) TranscriptDec 07, 2022
- Cardiff Oncology Inc at Piper Sandler Healthcare Conference TranscriptNov 29, 2022
- Cardiff Oncology Inc to Provide a Clinical and Corporate Update Call TranscriptSep 12, 2022
- Cardiff Oncology Inc to Discuss Updated Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer at ASCO-GI TranscriptJan 18, 2022
- Cardiff Oncology Inc to Discuss New Data from Lead Clinical Program in KRAS-mutated mCRC Webinar TranscriptSep 08, 2021
- Cardiff Oncology Inc at William Blair Biotech Focus Conference (Virtual) TranscriptJul 15, 2021
- Cardiff Oncology Inc KOL Webinar TranscriptApr 12, 2021
- Cardiff Oncology Inc Discusses KRAS Mutations in Cancer TranscriptOct 14, 2020
- Cardiff Oncology, Inc. - Special Call TranscriptSep 23, 2020
- Cardiff Oncology Inc Onvansertib Clinical Trials TranscriptMay 18, 2020
- Trovagene Inc at Needham Healthcare Conference TranscriptApr 15, 2020
- Trovagene Inc Business Update Conference Call TranscriptJun 07, 2019
Cardiff Oncology Inc at JMP Securities Hematology Oncology Summit (Virtual) Transcript
Welcome to Day 2 of our annual JMP Hematology and Oncology Conference. My name is Silvan Türkcan and I'm Senior Analyst covering precision medicines here at JMP Securities. It's my pleasure to host Mark Erlander, Chief Executive Officer of Cardiff Oncology. Thank you so much for joining us today.
Well, thank you, Silvan. I really appreciate the invite and the opportunity to tell everybody a little bit about what we're doing at Cardiff Oncology.
True, yes. And obviously, it's a very important day for KRAS today, and you're forging ahead with onvansertib development in RAS-mutated tumors. So looking forward to your presentation.
Okay. All right. Well, let me get started then. What is the -- why would you want to invest in Cardiff Oncology? What's the what, where, and why? Really onvansertib, we've
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)